Skip to main content
Clinical Trials/NCT00399737
NCT00399737TerminatedPhase 1

Effects of Peptides Derived From Fermented Milk on Blood Pressure Regulation System in Healthy Volunteers.

Assistance Publique - Hôpitaux de Paris2 sites in 1 country12 target enrollmentStarted: October 2005Last updated:
Conditions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Terminated
Enrollment
12
Locations
2
Primary Endpoint
ACE activity

Study Overview

Brief Summary

Several milk proteins are precursors of peptides, released during fermentation, which possess various biochemical and physiological properties. Among them, some peptides have been reported to inhibit angiotensin-converting enzyme (ACE) in vitro (an enzyme implicated in blood pressure regulation) and to lower blood pressure (BP). in hypertensive rats and in a small sample of patients with hypertension. One possible mechanism for the BP lowering effect is inhibition of ACE. Prior investigating BP lowering effect of these peptides in a large cohort of hypertensive patients, it is necessary to assess in depth their potency to inhibit ACE in vivo in humans and to compare it to that induced by a well-known ACE inhibitor.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Prevention
Masking
None

Eligibility Criteria

Ages
18 Years to 35 Years (Adult)
Sex
Male
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Healthy male volunteers
  • aged between 18 and 35 years
  • informed written consent

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

ACE activity

Secondary Outcomes

  • kinetics/dynamics

Investigators

Study Sites (2)

Loading locations...

Similar Trials